Aerie Pharmaceuticals' ROCK Inhibitor, AR-12286, Demonstrates Positive Results In Glaucoma Patients In A Phase 2a Study
Links shared publicly online about this topic.
- 1,651total visits
Aerie Pharmaceuticals' ROCK Inhibitor, AR-12286, Demonstrates Positive Results In Glaucoma Patients In A Phase 2a Study
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, announced positive results from a Phase 2a study of its Rho-kinase (ROCK)
View full resource at medicalnewstoday.com
Tags: Glaucoma, Pharma, Biotech
Most Recently Shared on October 25, 2009 at 12:45 pm By:
Aerie Pharmaceuticals' ROCK Inhibitor, AR-12286, Demonstrates Positive Results In Glaucoma Patients In A Phase .. http://bit.ly/hHIWU
Advertisement
